Shipment of Investigational Oral Agents to Participants in CCTG Clinical Trials

As clinical trial sponsor, the Canadian Cancer Trials Group (CCTG) is responsible for the oversight of the investigational medicinal product(s) (IMPs) used in its clinical trials. CCTG’s policies and requirements are intended to ensure participant safety and adherence with applicable regulations. Effective September 27, 2023 CCTG will permit oral investigational agents at ambient temperature (15 - 30°C) to be shipped directly to participants when circumstances prevent the participant from being seen at the centre and it is in the best interest for continuity of care of the participant. Direct shipments of oral IMP to participants are not intended to replace protocol required in-person study visits and assessments.

For additional details please refer to Guidance for Shipment of Oral Investigational Agents to Participants in Clinical Trials Sponsored by the Canadian Cancer Trials Group posted to the CCTG policies webpage.